Zürich (ots) - Der Verein Campaigning Summit Switzerland erhält den eidgenössischen Ritterschlag ...
ViroPharma is Proud to be a Friend of Rare Disease Day 2013!
Maidenhead, England (ots/PRNewswire) - --Rare Disease Day takes place on 28 February 2013 and this year's theme
focuses on 'Rare Disorders without Borders'--
--ViroPharma Incorporated is an international biopharmaceutical company committed to supporting patients with serious diseases for which there is an unmet medical
ViroPharma Incorporated , an international biopharmaceutical company committed to supporting patients with serious diseases for which there is an unmet medical need, today announced its participation in the sixth international Rare Disease Day. Rare Disease Day is coordinated by the European Organisation for Rare Diseases (EURORDIS) and by the National Organization for Rare Disorders (NORD) in the US and encourages patient organisations from across the globe to organise awareness-raising activities around this year's theme 'Rare Disorders without Borders'.
This year's theme focuses on helping to drive cross-border cooperation for diseases which affect only a few people in each country and for which expertise is scarce and scattered. There are more than 6,000 rare diseases affecting more than 60 million people in Europe and the US alone. Most of these diseases are genetic, serious, chronic and debilitating, and 50 percent of rare diseases touch children.
"ViroPharma is a proud member of EURORDIS and is delighted to be participating in this year's Rare Disease Day. At ViroPharma, we are committed to improving the lives of patients and believe in the value of this year's theme to create a network of solidarity for patients living with these diseases," said Thierry Darcis, Vice President, General Manager, ViroPharma, Europe. "We understand the isolation felt by many people living with rare diseases, and will continue to deliver solutions that address critical gaps in care for patients living with few, if any, clinical treatment options."
ViroPharma provides novel treatment solutions for patients living with rare diseases including hereditary angioedema, adrenal insufficiency, prolonged, acute, convulsive seizures, and Clostridium difficile infection.
As part of its commitment to improving the lives of patients with rare diseases in Europe, ViroPharma sponsors and funds educational initiatives including:
- The Hereditary Angioedema Burden of Illness Study in Europe (HAE-BOIS-Europe), an innovative, patient-centric, multi-country study of the humanistic and economic burden of HAE to address and improve current knowledge gaps surrounding the condition. - The PERFECT(TM) (Practices in Emergency and Rescue medication For Epilepsy managed with Community administered Therapy) Initiative, which aims to document and communicate first of its kind data on the impact of conflict of policy, guidelines and actual practice in the care of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents in the non-hospital setting.
ViroPharma Incorporated is based in Exton, Pennsylvania, US, and also has offices in Canada and in eight European countries including Belgium, France, Germany, Italy, Spain, Sweden, Switzerland and the United Kingdom. ViroPharma is continuing to grow its footprint and presence in Europe, and to support this growth set up its first European subsidiary in 2007, leveraging in Europe the company's expertise in the development and commercialisation of biotechnology products, and in business development.
Forward Looking Statements
Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events, including our ability to continue to deliver solutions that address critical gaps in care for patients living with few, if any, clinical treatment options. There can be no assurance that we will be successful in our efforts to continue to deliver solutions in the future. These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K for the year ended December 31, 2012 and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission for the periods ended March 31, 2012, June 30, 2012 and September 30, 2012, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward-looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercialising novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few, if any, clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, adrenal insufficiency, and C. difficile infection (CDI). Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and healthcare professionals we serve.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
1. Rare Disorders without Borders. Available at: http://www.rarediseaseday.org/article/rare-disorders-solidarity-has-no-border. Last accessed January 2013.
VIROPHARMA INCORPORATED Contacts: Thierry Darcis, Vice President,
General Manager, ViroPharma, Europe, Phone: +44-(0)20-7572-1222; Emma
(Media Enquiries), PR, Advocacy & Communications Manager, Phone: